Financial Performance - The company's operating revenue for 2024 was approximately ¥2.68 billion, a decrease of 1.46% compared to ¥2.72 billion in 2023[25]. - The net profit attributable to shareholders for 2024 was approximately -¥101.86 million, representing a decline of 138.02% from ¥267.91 million in 2023[25]. - The cash flow from operating activities for 2024 was approximately ¥382.43 million, down 37.76% from ¥614.46 million in 2023[25]. - The basic earnings per share for 2024 was -¥0.68, a decrease of 137.99% compared to ¥1.79 in 2023[25]. - Total assets at the end of 2024 were approximately ¥4.60 billion, a decrease of 4.51% from ¥4.82 billion at the end of 2023[25]. - The net assets attributable to shareholders at the end of 2024 were approximately ¥2.10 billion, down 8.30% from ¥2.29 billion at the end of 2023[25]. - The company reported a quarterly operating revenue of ¥675.88 million in Q1 2024, with a decline in revenue to ¥541.58 million in Q4 2024[27]. - The net profit attributable to shareholders in Q4 2024 was -¥117.70 million, following a positive net profit in the first two quarters[27]. - The company experienced a significant drop in net profit after deducting non-recurring gains and losses, with a figure of -¥85.22 million for 2024 compared to ¥197.81 million in 2023[25]. - The weighted average return on equity for 2024 was -4.65%, a decrease of 16.86% from 12.21% in 2023[25]. - The company reported a non-operating loss of approximately ¥16.64 million in 2024, a significant decrease from a profit of ¥70.1 million in 2023[32]. Market and Industry Trends - In 2024, the company's revenue from refractive and optical projects experienced a slight decline due to a slowdown in overall demand and intensified industry competition[4]. - The implementation of national centralized procurement policies for cataract artificial lenses starting May 2024 has put pressure on the company's cataract project revenue[4]. - The company is positioned in a growing ophthalmic medical service market, with a significant increase in myopia prevalence from 39.2% in 2016 to 47.1% in 2020[36]. - The cataract surgery penetration rate in China remains low despite rapid growth in the number of surgeries over the past decade, indicating room for further market expansion[37]. - The overall myopia rate among children and adolescents in China is 51.9%, highlighting a critical need for effective prevention measures[36]. - The National Health Commission's "14th Five-Year" plan aims for a 90% coverage rate for eye health checks among children aged 0-6 by 2025, which will enhance market opportunities[37]. - The market for myopia prevention products is expected to grow as public awareness increases, with products like orthokeratology lenses gaining traction[36]. Strategic Initiatives and Investments - The company has accelerated its investment expansion, opening multiple new hospitals in 2022, 2023, and 2024, including locations in Kunming, Nanchang, and Shanghai[5][6]. - New hospitals are currently in the market cultivation phase, leading to slower revenue growth and increased operational costs, including depreciation and labor expenses[6]. - The company plans not to distribute cash dividends, issue bonus shares, or increase share capital from reserves[7]. - The company is focusing on enhancing service capabilities in pediatric myopia prevention and elderly eye disease treatment as part of its strategic initiatives[37]. - The company is committed to adapting to the evolving healthcare landscape, leveraging technological advancements to meet the rising demand for personalized eye care solutions[35]. - The company is actively responding to the national strategy for myopia prevention and control, establishing a personalized vision management system[56]. - The company has established a "full-cycle eye health service system" focusing on pre-diagnosis, diagnosis, and post-diagnosis management[47]. Technological Advancements - AI technology is rapidly penetrating the eye care sector, optimizing diagnosis and treatment processes, and facilitating a shift towards intelligent and precise medical services[44]. - AI algorithms are being utilized for real-time monitoring of eye pressure and personalized rehabilitation plans for cataract patients, significantly improving post-operative satisfaction[45]. - The introduction of AI in operational areas is enhancing scheduling, cost monitoring, and patient follow-up, thereby increasing operational efficiency and patient compliance[45]. - The company is advancing its digital transformation by integrating AI, internet, and big data technologies to reconstruct service models and business processes[112]. - The company plans to create an integrated online and offline service loop, enhancing patient convenience through upgraded internet hospital functionalities and AI-driven customer service[113]. Research and Development - The company published 103 academic papers and participated in the formulation of 13 industry standards in 2024, enhancing its academic influence[58]. - The company is conducting research on the effectiveness and safety of CLASS surgery for different stages of glaucoma[71]. - A new digital corneal reshaping lens is being developed to improve vision in patients with high myopia[72]. - Clinical studies are ongoing to evaluate the effectiveness of new surgical techniques for retinal detachment and chronic dacryocystitis[72]. - The number of R&D personnel increased to 93 in 2024, up from 76 in 2023, representing a growth of 22.37%[74]. - The company is investing in new product development, with a budget allocation of 500 million for R&D in the upcoming fiscal year[138]. Corporate Governance and Compliance - The company has established a transparent performance evaluation and incentive mechanism for senior management, ensuring compliance with legal regulations[127]. - The company has revised several management systems to enhance information disclosure, aiming for accurate and timely communication with investors[127]. - The company maintains independence from its controlling shareholders in terms of assets, personnel, finance, organization, and business operations[129]. - The company has a complete and clear ownership of assets, including land, properties, medical facilities, trademarks, and patents[129]. - The company has established an independent financial accounting system and maintains separate bank accounts from its controlling shareholders[129]. - The company has not faced any regulatory criticism regarding information disclosure during the reporting period[127]. Social Responsibility and ESG Initiatives - The company invested over 5 million yuan in social welfare initiatives, benefiting over 100,000 people in rural areas[176]. - The company provided over 21,000 pairs of free glasses and conducted more than 250 free surgeries for underprivileged children and elderly individuals[176]. - The company actively adheres to environmental regulations and has not faced any administrative penalties related to environmental issues during the reporting period[174]. - The company emphasizes the integration of ESG principles into its corporate culture and daily operations[175]. - The company is committed to sustainable development and social responsibility, balancing environmental, economic, and social values[175]. Shareholder Relations and Financial Management - The company announced a cash dividend of RMB 4.00 per 10 shares, totaling RMB 59,545,512.40, which accounts for 22.23% of the net profit attributable to shareholders for the reporting period[123]. - The company completed the acquisition of Dali Optometry Hospital in December 2024, enhancing its market share in the Yunnan region[120]. - The company has established a three-year shareholder return plan to balance performance growth with shareholder returns, promoting a sustainable development model[116]. - The company will not distribute profits in 2024 due to anticipated losses and to ensure sufficient funds for long-term development[164]. - The company has approved a plan to stabilize its stock price for three years post-IPO, triggered if the stock price closes below the audited net asset value per share for 20 consecutive trading days[193].

证券代码：301239 证券简称：普瑞眼科 公告编号：2025-008 特此公告。 成都普瑞眼科医院集团股份有限公司 董事会 二〇二五年四月八日 成都普瑞眼科医院集团股份有限公司 关于变更持续督导保荐代表人的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 成都普瑞眼科医院集团股份有限公司（以下简称"公司"）于近日收到国泰海通 证券股份有限公司（以下简称"国泰海通"）出具的《关于更换持续督导保荐代表人 的函》。国泰海通作为公司首次公开发行股票并在创业板上市的保荐机构，原指派田 卓玲女士和朱玉峰先生担任保荐代表人，负责保荐工作及持续督导工作，持续督导期 至2025年12月31日。 原保荐代表人朱玉峰先生因工作安排原因，无法继续从事对公司的持续督导工作。 为保证持续督导工作的有序进行，国泰海通现委派保荐代表人李沁杭先生（简历详见 附件）接替朱玉峰先生继续履行持续督导工作。 本次变更后，公司首次公开发行股票的持续督导保荐代表人为田卓玲女士和李沁 杭先生，持续督导期至中国证券监督管理委员会和深圳证券交易所规定的持续督导义 务结束为止。 本次变更持续督导保荐代表人的 ...

证券代码：301239 证券简称：普瑞眼科 公告编号：2025-011 成都普瑞眼科医院集团股份有限公司 关于使用部分闲置募集资金暂时补充流动资金的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 成都普瑞眼科医院集团股份有限公司（以下简称"公司"）于2025年4月7 日召开第三届董事会第三十次会议和第三届监事会第二十一次会议，分别审议通 过了《关于使用部分闲置募集资金暂时补充流动资金的议案》，同意公司使用总 额不超过人民币25,000万元的闲置募集资金暂时补充流动资金，使用期限为自第 三届董事会第三十次会议审议通过之日起不超过12个月，到期归还至募集资金专 用账户。国泰海通证券股份有限公司（以下简称"保荐机构"）对该事项出具了 无异议的核查意见，本事项无需提交股东大会审议。现将相关情况公告如下： 一、募集资金的基本情况 经中国证券监督管理委员会《关于同意成都普瑞眼科医院股份有限公司首次 公开发行股票注册的批复》（证监许可[2022]587号）同意注册，公司首次公开 发行人民币普通股（A股）股票37,404,762股，每股面值人民币1.00元，每股发 行价 ...

国泰海通证券股份有限公司 关于成都普瑞眼科医院集团股份有限公司 使用部分闲置募集资金暂时补充流动资金的核查意见 国泰海通证券股份有限公司（以下简称"国泰海通证券"或"保荐机构"）作为 成都普瑞眼科医院集团股份有限公司（以下简称"普瑞眼科"或"公司"）首次公开 发行股票并在创业板上市持续督导保荐机构，根据《证券发行上市保荐业务管理 办法》、《上市公司监管指引第2号——上市公司募集资金管理和使用的监管要求 （2022年修订）》、《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市 公司自律监管指引第2号-创业板上市公司规范运作》等有关规定，对公司使用部 分闲置募集资金暂时补充流动资金的事项进行了核查，具体情况如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于同意成都普瑞眼科医院股份有限公司首次 公开发行股票注册的批复》（证监许可[2022]587 号）同意注册，成都普瑞眼科医 院股份有限公司首次公开发行人民币普通股（A 股）股票 37,404,762 股，每股面 值人民币 1.00 元，每股发行价格为 33.65 元，募集资金总额为 1,258,670,241.30 元，扣除发行费用（含税）后，实际 ...

证券代码：301239 证券简称：普瑞眼科 公告编号：2025-012 成都普瑞眼科医院集团股份有限公司 关于使用暂时闲置募集资金（含超募资金） 及自有资金进行现金管理的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 重要内容提示： 1．投资种类：成都普瑞眼科医院集团股份有限公司（以下简称"公司"） 拟使用闲置募集资金（含超募资金）及自有资金进行现金管理，其中募集资金 购买安全性高、流动性好、风险低、期限不超过12个月或可转让可提前支取的 产品，包括但不限于结构性存款、协定存款等，不会影响募集资金投资计划正 常进行；自有资金拟购买安全性高、流动性好的现金管理产品。 2．投资金额：为提高公司资金使用效率，在确保不影响募集资金投资计划 正常进行，不影响公司正常运营及确保资金安全的情况下，拟使用不超过人民 币40,000.00万元（含本数）的闲置募集资金（含超募资金）及不超过人民币 40,000.00万元（含本数）的自有资金进行现金管理。在上述额度内，资金可以 滚动使用，期限自前次闲置募集资金及自有资金现金管理的授权到期之日起12 个月内，即2025年4月22 ...

证券代码：301239 证券简称：普瑞眼科 公告编号：2025-010 成都普瑞眼科医院集团股份有限公司 第三届监事会第二十一次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、监事会会议召开情况 成都普瑞眼科医院集团股份有限公司（以下简称"公司"）第三届监事会 第二十一次会议通知于2025年4月1日以书面、电子邮件的方式向全体监事发出 并送达，会议于2025年4月7日以通讯方式召开。本次会议应出席监事3人，实际 出席监事3人。会议由监事会主席雷德芳女士主持。本次会议的召集、召开和表 决程序符合《中华人民共和国公司法》等法律、法规、规范性文件以及《公司 章程》的有关规定。 二、监事会会议审议情况 经与会监事认真审议，表决了以下议案： 表决情况：同意3票，反对0票，弃权0票。 三、备查文件 1．第三届监事会第二十一次会议决议。 特此公告。 （一）审议通过《关于使用部分闲置募集资金暂时补充流动资金的议案》 经审议，监事会认为：公司使用总额不超过人民币25,000万元的闲置募集 资金暂时补充流动资金，是在保证募集资金投资项目建设的资金需求、保证募 集 ...

经中国证券监督管理委员会《关于同意成都普瑞眼科医院股份有限公司首次 公开发行股票注册的批复》（证监许可[2022]587 号）同意注册，成都普瑞眼科医 院股份有限公司首次公开发行人民币普通股（A 股）股票 37,404,762 股，每股 面 值 人 民 币 1.00 元 ， 每 股 发 行 价 格 为 33.65 元 ， 募 集 资 金 总 额 为 1,258,670,241.30 元，扣除发行费用（含税）后，实际募集资金净额为 1,098,935,692.69 元。天健会计师事务所（特殊普通合伙）已于 2022 年 6 月 27 日对公司上述募集资金到位情况进行了审验，并出具了天健验[2022]314 号《成 都普瑞眼科医院股份有限公司验资报告》。 关于成都普瑞眼科医院集团股份有限公司 使用暂时闲置募集资金（含超募资金）及自有资金进行现金管 理的核查意见 国泰海通证券股份有限公司（以下简称"国泰海通证券"或"保荐机构"）作为 成都普瑞眼科医院集团股份有限公司（以下简称"普瑞眼科"或"公司"）首次公开 发行股票并在创业板上市持续督导保荐机构，根据《证券发行上市保荐业务管理 办法》、《上市公司监管指引第2号—— ...

第三届董事会第三十次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、董事会会议召开情况 证券代码：301239 证券简称：普瑞眼科 公告编号：2025-009 成都普瑞眼科医院集团股份有限公司 成都普瑞眼科医院集团股份有限公司（以下简称"公司"）第三届董事会 第三十次会议通知于2025年4月1日以书面、电子邮件的方式向全体董事发出并 送达，会议于2025年4月7日以现场结合通讯方式召开。本次会议应出席董事7人， 实际出席董事7人。会议由董事长徐旭阳先生主持，公司部分监事和高级管理人 员列席会议。本次会议的召集、召开和表决程序符合《中华人民共和国公司法》 等法律、法规、规范性文件以及《公司章程》的有关规定。 二、董事会会议审议情况 经与会董事认真审议，表决了以下议案： （一）审议通过《关于使用部分闲置募集资金暂时补充流动资金的议案》 经审议，公司董事会同意公司使用总额不超过人民币25,000万元的闲置募 集资金暂时补充流动资金，使用期限为自本次董事会审议通过之日起不超过12 个月，到期归还至募集资金专用账户。 保荐机构国泰海通证券股份有限公司出 ...

Core Viewpoint - The eye health awareness among the Chinese population is increasing, leading to significant growth in the ophthalmic optical instrument industry, which is expected to reach a market size of approximately 4 billion yuan by 2024 [1][15]. Industry Overview - Ophthalmic optical instruments are essential for diagnosing and treating eye diseases, including devices like computer visual field analyzers, automatic refractors, corneal topographers, and fundus cameras [3][4]. - The industry has seen remarkable advancements in technology and product development, with domestic companies enhancing their R&D capabilities and launching high-quality products [1][15]. Market Growth - The market size of China's ophthalmic optical instrument industry has been continuously growing from 2017 to 2023, with projections indicating it will reach around 4 billion yuan in 2024 [1][15]. - The increasing prevalence of age-related eye diseases and lifestyle changes, such as prolonged use of electronic devices, are driving the demand for ophthalmic medical services [13][25]. Industry Chain - The upstream of the ophthalmic optical instrument industry includes suppliers of optical glass and plastic, which are crucial for manufacturing high-quality instruments [9][11]. - The midstream consists of various manufacturers of ophthalmic optical instruments, while the downstream includes hospitals, clinics, and optical shops where these instruments are utilized [9]. Competitive Landscape - The market concentration in the ophthalmic optical instrument industry is relatively high, with a few companies dominating specific product areas like fundus cameras and OCT devices [17][18]. - Key players in the industry include companies like 图拜医疗, 康捷医疗, and 新眼光, which are focusing on high-end product development [17][18]. Policy Environment - Recent policies have been introduced to promote the standardization and regulation of the medical device industry, providing favorable conditions for the growth of the ophthalmic optical instrument sector [4][6]. - The government aims to enhance the quality and safety of medical devices, ensuring a robust regulatory framework by 2035 [6]. Future Trends - The market is expected to further penetrate various healthcare institutions, with handheld devices likely to see widespread adoption in grassroots medical facilities [23]. - The integration of artificial intelligence and big data into ophthalmic optical instruments is becoming mainstream, leading to the development of smart devices that enhance diagnostic capabilities [24][25].

证券代码：301239 证券简称：普瑞眼科 公告编号：2025-007 成都普瑞眼科医院集团股份有限公司 关于控股股东部分股份解除质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、股东股份解除质押及累计质押的基本情况 成都普瑞眼科医院集团股份有限公司（以下简称"公司"）近日接到控股 股东成都普瑞世纪投资有限责任公司（以下简称"普瑞投资"）的通知，获悉 普瑞投资将其所持有的公司部分质押股份办理了解除质押业务。具体事项如下： | 股东 | 是否为控股股 东或第一大股 | 本次解除质 | 占其所 | 占公司 | 质押起 | 质押解 | 质权 | | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | 东及其一致行 | 押数量 | 持股份 | 总股本 | 始日 | 除日 | 人 | | | | （股） | 比例 | 比例 | | | | | | 动人 | | | | | | | | | | | | | | | 中国 | | | | | | | | | 民生 | | | | | | | | | 银行 ...